QLC1101 + QL1706

QLC1101 + QL1706 is an investigational combination therapy under clinical evaluation for the treatment of advanced solid tumors, specifically in patients harboring KRAS G12D mutations. QLC1101's exact mechanism has not been specified in accessible resources, but it is being tested in combination with other anti-cancer agents. QL1706 is a bifunctional monoclonal antibody mixture targeting immune checkpoint proteins PD-1 and CTLA-4. It consists of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, produced by a single cell line, which allows for tailored pharmacokinetics and potentially improved anti-tumor immune responses. This combination aims to leverage the synergistic effect of direct KRAS G12D targeting (via QLC1101) and dual immune checkpoint blockade (via QL1706) to enhance anti-tumor efficacy, particularly in populations with actionable genetic alterations in KRAS. The drugs are being developed and evaluated by Qilu Pharmaceutical[5][2][3].